

parties can take pride in, and one which, more than anything, benefits all seniors across the country.

WORKING TOGETHER TO HELP
OUR NATION'S SENIOR CITIZENS

HON. HOWARD P. "BUCK" McKEON

OF CALIFORNIA

IN THE HOUSE OF REPRESENTATIVES

Tuesday, February 23, 1999

Mr. McKEON. Mr. Speaker, today, Mr. BARRETT of Nebraska, Mr. MARTINEZ, Mr. CLAY, Chairman GOODLING and I are introducing the Older Americans Act Amendments of 1999. Our hope is that this bill will be the first step in an ongoing bipartisan effort to reauthorize the Older Americans Act. Nonetheless, it is important to remember that there is much work to be done when it comes to reforming and streamlining the provisions of the Older Americans Act.

Today's version of the Older Americans Act Amendments of 1999 represents a good-faith effort on the part of both parties to work together in this important venture. Over the course of the next several months, we are committed to having an open dialogue with all those who are involved in administering the Act's many programs. However, it is absolutely imperative that we keep those who we are trying to help—the frail and elderly—foremost in our minds.

INTRODUCTION OF THE GENERIC
DRUGS ACCESS ACT OF 1999

HON. FRANK PALLONE, JR.

OF NEW JERSEY

IN THE HOUSE OF REPRESENTATIVES

Tuesday, February 23, 1999

Mr. PALLONE. Mr. Speaker, the high cost of prescription drugs is one of the most pressing health care issues confronting the country's senior citizens, employers, managed care plans, state and federal drug programs. Controlling drug costs will be no easy task. One time-tested method, however, is timely access and availability of generic medicines once the patent on brand name drugs expires.

Generic competition has a dramatic impact on pharmaceutical costs. When a generic drug first comes onto the market, it typically costs 30 percent less than the brand name version. After two years on the market, the prices drop further to 60 or 70 percent of the brand name drug. The price of some generic drugs drop by as much as even 90 percent.

While these competitively priced alternatives are good for consumers, employers and government purchasers, they are not good for the brand name producer trying to maintain and protect monopolistic pricing. If there is no generic alternative available, consumers who need medicine have no choice but to buy the available brand drug and pay whatever it costs. It is for this reason that brand name drug companies launch aggressive campaigns to block or delay generic competition.

One tactic used by the brand industry to prevent generics from reaching the consumer

is to convince state legislatures to pass unnecessary restrictions to the substitution of generic versions of brand name drugs. These restrictive laws are being advanced despite a scientific finding by the Food and Drug Administration (FDA) that the generic drug is equivalent and substitutable to the brand name product. The state campaign is nothing more than an attempt by the brand name companies to protect market share.

If these tactics are successful with the states, generic manufacturers could end up having to comply with 50 different sets of state laws before their products could ever reach the consumer. It would render the FDA stamp of approval meaningless. And it will only add extraordinary hoops for doctors and pharmacists to jump through before a generic medicine is dispensed. The ultimate losers are the senior citizens and other prescription drug purchasers who will be denied the access to equivalent generics and are forced to continue paying excessive brand prices for their medicines.

The bill I am introducing today, the Generic Drugs Access Act, would prevent drug companies from gaming the system. Very simply, this bill prohibits states from passing laws keeping generic drugs off the market once the FDA has determined that a generic drug is "therapeutically equivalent" to a brand name product. Most importantly, it will ensure that generic drugs get to the market in a timely fashion and provide consumers with access to low cost alternatives at the earliest possible time.

I urge my colleagues to lend their support to the effort to ensure low cost alternatives to brand name drugs are readily available to consumers and cosponsor the Generic Drugs Access Act of 1999.

RETURN THE FORESTS BACK TO
THE PEOPLE

HON. MARY BONO

OF CALIFORNIA

IN THE HOUSE OF REPRESENTATIVES

Tuesday, February 23, 1999

Mrs. BONO. Mr. Speaker, I rise to announce the introduction of the Forest Tax Relief Act (H.R.—), an important bill to let all our citizens enjoy the forests free from burdensome taxes. I am proud to announce that I have co-authored this bi-partisan bill with my dear colleague, Representative LOIS CAPPS (D-CA.) Our original co-sponsors include Congressman MERRILL COOK (R-UT), Congressman PETER DEFAZIO (D-CA) and Congresswoman JO ANN EMERSON (R-MO).

Due to enabling legislation passed by a previous Congress, the United States Forest Service has implemented a new pilot project charging day users a per car fee to park on public lands. Dubbed the "Adventure Pass" by the U.S. Forest Service, this is nothing but a new tax on using public lands. Many of my constituents question the fairness and merits of this tax, and I share their concern. This tax goes against the concept of experiencing our free and open land making it a hardship on locals and visitors alike.

Within the forests of the 44th Congressional district, the per car fee for an Adventure Pass

is \$5. To residents in the communities of Idillywild, Anza, Hemet and San Jacinto and tourists who come to enjoy these precious lands, this fee is a source of much controversy. We have come to expect the freedom to enjoy this area without the inconvenience and tax imposed on us today.

To tax the Great Outdoors is offensive to the very concept of the national forest system. The forests are for the entire nation and therefore should be supported through the traditional funding process. Under this plan, Congress taxes Americans twice. It is now time to remedy this situation.

Mr. Speaker, I believe we are deterring individuals from discovering the wonder and beauty of our National Forests. We must encourage people to visit, not discourage them from doing so. When tourists go elsewhere, it hurts small businesses and it hurts our efforts to educate individuals on the importance of protecting this precious national resource. This tax serves as a barrier to working families, hikers, nature lovers and all those desiring access to our national forests.

I hope my colleagues will join me in supporting this effort to return the forests back to the people.

PERSONAL EXPLANATION

HON. MARK UDALL

OF COLORADO

IN THE HOUSE OF REPRESENTATIVES

Tuesday, February 23, 1999

Mr. UDALL of Colorado. Mr. Speaker, on February 2, while I was meeting in my office with some constituents, an apparent problem with the bell system led to my inadvertently missing the vote on rollcall No. 7, passage of H.R. 68—the Small Business Investment Company Technical Corrections Act. Had I been present, I would have voted "yes."

TRIBUTE TO MRS. GERTRUDE S.
PARIS

HON. JAMES E. CLYBURN

OF SOUTH CAROLINA

IN THE HOUSE OF REPRESENTATIVES

Tuesday, February 23, 1999

Mr. CLYBURN. Mr. Speaker, I ask my colleagues to join me in paying tribute to a loving mother, grandmother and great-grandmother, Mrs. Gertrude S. Paris.

Mrs. Paris was born in Rochester, New York, on February 27, 1899, to Charles and Elizabeth Steul. In November 1938 she married Earl A. Paris (deceased). They had two children, John Walter Paris and Beverly Paris Dox. Mrs. Paris has seven grandchildren and six great-grandchildren who affectionately address her as "Gramma."

Mrs. Paris has led an extremely active life. She maintained her home in Rochester until her early 90's, mowing her own lawn and tending her garden. She was a founding member of the Rochester Garden Club, and an avid bridge player. Her favorite pastime was "a pound of chocolate and a good book." Mrs. Paris became a constituent of mine at the age